NC
ADVM

Nexthera Capital’s Adverum Biotechnologies ADVM Stock Holding History

Nexthera Capital’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-50,118
Closed -$2.91M – 46
2018
Q1 		$2.91M Buy
+50,118
New +$3.12M 0.48% 37

Other funds holding ADVM

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Nexthera Capital's ADVM Position: Q2 2018 in Review

Nexthera Capital sold out of Adverum Biotechnologies (ADVM) in Q2 2018, closing a stake of 50,118 shares — an estimated $2.91M sold.

Nexthera Capital first reported a position in ADVM in Q1 2018 and held it in 1 quarter. The position peaked at $2.91M in Q1 2018. 100 funds tracked by Wall St. Rank hold ADVM as of Q2 2018.

  • Nexthera Capital reported no remaining Adverum Biotechnologies position as of Q2 2018 after selling out during the quarter.
  • Nexthera Capital sold 50,118 Adverum Biotechnologies shares in Q2 2018, an estimated $2.91M.
  • Nexthera Capital first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 1 quarter.
  • Nexthera Capital's Adverum Biotechnologies position peaked at $2.91M in Q1 2018.
  • 100 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2018.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.